Copyright © 2022 StrategyHelix Inc. All Rights Reserved.
Global Psoriatic Arthritis Treatment Market - Outlook and Forecast 2022-2027
The global market for psoriatic arthritis treatment is projected to reach USD 12.46 billion by 2027, growing at a compound annual growth rate (CAGR) of 8.09% from USD 7.81 billion in 2021. Psoriatic arthritis is a chronic inflammatory rheumatic disease characterized by joint pain, stiffness, swelling, erosion, and bone formation. It affects up to 30% of patients with psoriasis, typically those aged between 30 and 60 years. While it often develops about 10 years after psoriasis, some individuals may experience PsA before or without psoriasis. Both men and women can be affected, with women contributing more to the global market due to a higher risk of developing PsA. Estimates suggest that PsA affects over 2 million people in the European Union and around 0.5 million in the United States.
The exact cause of PsA is not yet known, but family history is a significant factor, as approximately 40% of individuals with the disease have a family member affected by psoriasis or arthritis. Risk factors include obesity, severe psoriasis, nail disease, and trauma or deep lesions at trauma sites.
|No. of Pages||
USD 7.8 billion in 2020
Drug Class, Disease Type, Gender Type, Age Group, Severity Type, and Geography
|No. of Companies Mentioned||
Diagnosing psoriatic arthritis does not involve a specific test. Its symptoms resemble those of other arthritic conditions such as rheumatoid arthritis, reactive arthritis, and gout. Diagnosis may involve imaging techniques like X-rays, CT scans, ultrasound, MRI, and skin biopsies.
The treatment approach depends on the severity of pain, swelling, and stiffness. Mild cases may only require treatment when joint pain occurs and therapy can be discontinued when symptoms improve. Non-steroidal anti-inflammatory drugs like ibuprofen and naproxen are commonly used as initial treatment. If arthritis does not respond, disease-modifying anti-rheumatic drugs may be prescribed, including sulfasalazine, methotrexate, cyclosporine, and leflunomide. Combinations of these drugs might be used in some cases. Severe forms of PsA may benefit from azathioprine.
Other treatment options include biologics, starting with TNF inhibitors like adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab. Biologics targeting IL-17A inhibitors (secukinumab and ixekizumab), IL-12/23 inhibitor (ustekinumab), IL-23 inhibitors (risankizumab-rzaa and guselkumab), and other classes like abatacept have also demonstrated effectiveness. New oral medications such as tofacitinib, upadacitinib, and apremilast have shown efficacy too.
The psoriatic arthritis treatment market currently includes over 25 assets at various stages of development, with most industry-sponsored drugs in the Phase III stage. Emerging therapies for PsA include Bimekizumab, Tildrakizumab, SHR-0302, Neihulizumab, among others. These novel drugs are expected to alter the treatment landscape and offer improved safety and efficacy profiles compared to existing patented commercial drugs.
There are over 150 clinical trials in progress for psoriatic arthritis, with a majority in the Phase III stage. Most trials focus on the late-phase development, with 58% in Phase II/III & III and 41% in Phase I-II.
The psoriatic arthritis treatment market utilizes biological therapies such as anti-TNF and anti-interleukin antibodies. However, there is a demand for therapies with novel mechanisms of action (MOAs) that are less immunogenic than current options. New classes of therapies, including interleukin inhibitors, are gaining traction due to improved clinical profiles and convenient dosing.
The recent wave of biologic products for PsA treatment presents lucrative opportunities. Despite the availability of multiple therapies, there is still a need for improvement in the psoriatic arthritis treatment market. The research forecasts the launch of five new agents across eight major markets, including two IL inhibitors (Bimekizumab and Tildrakizumab) and two oral JAK inhibitors (Filgotinib and SHR0302), along with one oral TYK2 inhibitor (Deucravacitinib). The introduction of these late-stage drugs will drive growth in the global market.
Over the past seven years, therapies that target inflammatory pathways beyond TNF have emerged as options for treating PsA. IL-23/IL-17 axis inhibitors have proven to be highly effective, some already in use, while others are in development. Inhibition of IL-23 and IL-17 with monoclonal antibodies has shown significant therapeutic benefits in the psoriatic arthritis treatment market. The research expects a surge of innovation from the research and development pipeline in the next five years, leading to technological advancements that improve interventions and outcomes.
The market is segmented based on various factors, including drug class, disease type, gender type, age group, severity type, and geography.
Segmentation by Drug Class
Other classes of Drugs
Segmentation by Disease Type
Segmentation by Gender Type
Segmentation by Age Group
50 years and Below
50 years and Above
Segmentation by Severity Type
Segmentation by Geography
North America – US
Europe – Germany, France, UK, Italy, Spain
APAC – China, Japan
Drug Class: TNF-Alpha inhibitors currently hold a significant share of the global psoriatic arthritis treatment market. However, it is anticipated that interleukin inhibitors will experience the fastest growth during the forecast period. The recent approvals of interleukin inhibitors such as Skyrizi (risankizumab-rzaa) and Cosentyx (Secukinumab) are expected to drive the global psoriatic arthritis treatment market in the coming years.
Gender Type: In the gender type segment, women constitute a notable portion of the global psoriatic arthritis treatment market. This trend can be attributed to the increased risk of psoriatic arthritis among women in recent times.
Disease Type: Enthesitis is projected to hold a significant share of the market. However, Dactylitis is expected to be the fastest growing segment during the forecast period.
Age Group: Individuals below the age of 50 are expected to make up a substantial portion of the global psoriatic arthritis treatment market.
Severity Type: Among different severity types, individuals with a mild form of psoriatic arthritis are expected to account for a significant share of the market. However, those with a moderate form are anticipated to be the fastest growing segment in the coming years.
Geographically, the United States currently dominates the global psoriatic arthritis treatment market. This can be attributed to factors such as healthcare affordability, high levels of knowledge and awareness among the population, and advanced technological capabilities. Nonetheless, Germany is expected to exhibit rapid growth, with a high compound annual growth rate (CAGR) in the PsA drug industry. This can be attributed to increased access to and quality of healthcare, greater awareness about disease management, and rising healthcare expenditure in the region. The emergence of biosimilars in markets like China and Japan has the potential to bring about significant changes within their respective psoriatic arthritis therapeutic landscapes.
According to estimates from The research, China had the highest number of prevalent psoriatic arthritis cases in 2020, followed by Spain and the U.K. The growing prevalence of psoriatic arthritis is a key driver for the expansion of the psoriatic arthritis treatment market. In 2014, it was estimated that over two million people in the European Union were affected by PsA.
The global market for psoriatic arthritis treatment is characterized by the presence of numerous companies offering both generic drugs and patented/commercial drugs for the treatment of PsA. In 2013, the U.S. Food and Drug Administration (FDA) approved Stelara (Ustekinumab), an interleukin antibody, for the treatment of psoriatic arthritis. More recently, the FDA has approved other interleukins such as Skyrizi (risankizumab-rzaa) in 2022 and Cosentyx (secukinumab) in 2021 for PsA treatment. While generic products continue to hold a significant share of the psoriatic arthritis treatment market, the introduction of biologics and targeted therapies signals a shift in the therapeutic landscape.
Major players in the global psoriatic arthritis treatment market include AbbVie Inc., Johnson & Johnson, Takeda Pharmaceutical Co Ltd, Biogen Inc, UCB SA, Amgen, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, and Novartis. These companies are actively employing growth strategies to strengthen their product portfolios. Such strategies include collaborations and acquisitions, expanding their geographical footprint, investing in research and development, and manufacturing novel drugs to compete in the global market.
Other notable players operating in the psoriatic arthritis treatment market include Sun Pharmaceuticals, Bausch Health Companies Inc, Jiangsu HengRui Medicine Co. Ltd, Biocad Biopharmaceutical, Meiji Holdings Co Ltd, and Bio-Thera. These players are prioritizing research and development endeavors to develop technologically advanced and innovative psoriatic drugs. Additionally, they are entering into collaborations to maintain their position in the industry.
Key companies profiled in this report include AbbVie Inc., Johnson & Johnson, UCB SA, Amgen, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, Novartis, Samsung Bioepis, Boehringer Ingelheim, Mylan, Merck & Co., Inc, Coherus BioSciences, Inc, Sun Pharmaceuticals, Bausch Health Companies Inc, Jiangsu HengRui Medicine Co. Ltd, Biocad Biopharmaceutical, Meiji Holdings Co Ltd, Bio-Thera.
Key Questions Answered
What is the current size of the global psoriatic arthritis treatment market?
The global psoriatic arthritis treatment market is projected to reach a value of USD 12.46 billion by 2027.
What is the growth rate forecasted for the global psoriatic arthritis treatment market?
The global psoriatic arthritis treatment market is expected to grow at a compound annual growth rate (CAGR) of 8.09% from 2022 to 2027.
What are the key drivers of the growth in the psoriatic arthritis treatment market?
Factors such as the increasing adoption of biological therapies, the anticipated launch of emerging drugs, and the focus on developing novel drugs with innovative mechanisms are driving the growth of the market.
Who are the major vendors operating in the psoriatic arthritis treatment market?
AbbVie Inc., Johnson & Johnson, Takeda Pharmaceutical Co Ltd, Biogen Inc, UCB SA, Amgen, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, and Novartis are among the leading players in the global psoriatic arthritis treatment market. These companies are implementing various growth strategies to strengthen their product portfolios.
Which region has the largest market share in the global psoriatic arthritis treatment market?
The United States holds the largest share in the global psoriatic arthritis treatment market, primarily due to factors such as healthcare affordability, high level of knowledge and awareness among the population, and technological advancements in the region.